NCT00402649View on ClinicalTrials.gov

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

December 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)

Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.

Trial Locations (3)

21201

University of Maryland Baltimore, Baltimore

63104

Saint Louis University, St Louis

90502

UCLA Center For Vaccine Research, Torrance

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00402649 - Open-Label Study of H5 Vaccine in Participants of Protocol 04-077 | Biotech Hunter | Biotech Hunter